secwatch.observer — SEC 8-K summary
======================================

Issuer:     ILLUMINA, INC. (ILMN)
CIK:        0001110803
Form:       8-K
Filed at:   2026-06-23T13:08:49+00:00
Accession:  0001110803-26-000138
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Illumina appoints Eli Lilly's CSO Daniel Skovronsky to Board effective June 16, 2026
--------------------------------------------------------------------------------

- Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board effective June 16, 2026; Board expanded to 10 members.
- Skovronsky is Eli Lilly's Chief Scientific and Product Officer and President of Lilly Research Laboratories.
- He brings expertise in drug discovery, clinical development, and translational medicine to Illumina's genomics focus.
- Skovronsky will participate in the standard non-employee director compensation program described in April 9, 2026 proxy.
- He qualifies as an independent director under Nasdaq and SEC rules; will stand for election at 2027 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1110803/000111080326000138/0001110803-26-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1110803/000111080326000138/ilmn-20260616.htm
  HTML page:      https://secwatch.observer/filing/0001110803-26-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer